12:00 AM
 | 
Apr 14, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Latuda lurasidone regulatory update

Health Canada approved Latuda lurasidone to treat depressive episodes associated with bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate. FDA approved Latuda for the indication last July. The product...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >